

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Sanofi
Enrollment	526 participants

Key Eligibility Criteria

Inclusion (2)

- Participants who are scheduled to receive their first kidney transplant from a living or deceased donor.
- Participants with low to moderate immunological risk.

Exclusion (8)

- Deceased donor kidney graft qualified as expanded criteria donor or donor after cardiac death.
- Positive T or B cell crossmatch, or positive virtual crossmatch per local practice at screening.
- Participants receiving a kidney graft from HLA-identical living-related donors, or have current or previous solid organ, cell, or multi-organ transplantation, or paired kidney transplantation.
- Participants whose primary causes of ESKD are idiopathic FSGS, C3 glomerulopathy, lupus nephritis, or thrombotic microangiopathy
- Evidence of active or latent TB, HIV, HBV or HCV infection.

... and 3 more (see full listing online)

Locations (2 total)

Investigational Site Number : 0360003, Sydney, Australia
Investigational Site Number : 1560001, Shanghai, China